Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial

Abstract

OOC, an oral therapeutic peptide, achieves efficacy in controlling IGF-1 and GH after switching from injectable SRLs for up to 13 months, with a safety profile consistent with approved SRLs. OOC appears to be effective and safe as an acromegaly monotherapy.